Literature DB >> 12609839

Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival.

Kai-Da Wu1, Lisa M Orme, John Shaughnessy, Joth Jacobson, Bart Barlogie, Malcolm A S Moore.   

Abstract

We have investigated the significance of telomerase activity (TA) and telomere length (TL) in multiple myeloma (MM). The analyses were undertaken on CD138+ MM cells isolated from the marrow of 183 patients either at diagnosis or in relapse. There was heterogeneity in telomerase expression; 36% of the patients had TA levels comparable to those detected in normal plasma cells, and 13% of patients had levels 1- to 4-fold greater than in a neuroblastoma cell line control. The TL of MM cells was significantly shorter than that of the patients' own leukocytes; in 25% of patients, the TL measured less than 4.0 kbp. Analysis of TL distribution indicated selective TA-mediated stabilization of shorter telomeres when mean TL fell below 5.5 kbp. Unusually long (10.8-15.0 kbp) telomeres were observed in 7 patients, and low TA was observed in 5 of 7 patients, suggesting the operation of a TA-independent pathway of telomere stabilization. A strong negative correlation existed between TA and TL or platelet count. TL negatively correlated with age and with interleukin-6 (IL-6) and beta2-microglobulin levels. Various cytogenetic abnormalities, including those associated with poor prognosis, strongly correlated with TA and, to a lesser extent, with short TL. High TA and short TL defined a subgroup of patients with poor prognosis. At 1 year the survival rate in patients with TA levels lower than 25% of neuroblastoma control and TL greater than 5.5 kbp was 82%, whereas in patients with higher TA and shorter TL the survival rate was 63% (P =.004). The 2-year survival rate for patients with TA levels lower than 25% was 81%, and it was 52% in those with higher TA levels (P <.0001).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12609839     DOI: 10.1182/blood-2002-11-3451

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

1.  Altered mRNA expression of telomere-associated genes in monoclonal gammopathy of undetermined significance and multiple myeloma.

Authors:  Julieta Panero; Jorge Arbelbide; Dorotea Beatriz Fantl; Hernán García Rivello; Dana Kohan; Irma Slavutsky
Journal:  Mol Med       Date:  2010-07-14       Impact factor: 6.354

2.  Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.

Authors:  Aaron P Rapoport; Nicole A Aqui; Edward A Stadtmauer; Dan T Vogl; Hong-Bin Fang; Ling Cai; Stephen Janofsky; Anne Chew; Jan Storek; Gorgun Akpek; Ashraf Badros; Saul Yanovich; Ming T Tan; Elizabeth Veloso; Marcela F Pasetti; Alan Cross; Sunita Philip; Heather Murphy; Rita Bhagat; Zhaohui Zheng; Todd Milliron; Julio Cotte; Andrea Cannon; Bruce L Levine; Robert H Vonderheide; Carl H June
Journal:  Blood       Date:  2010-10-28       Impact factor: 22.113

3.  MUC1-C drives MYC in multiple myeloma.

Authors:  Ashujit Tagde; Hasan Rajabi; Audrey Bouillez; Maroof Alam; Reddy Gali; Shannon Bailey; Yu-Tzu Tai; Teru Hideshima; Kenneth Anderson; David Avigan; Donald Kufe
Journal:  Blood       Date:  2016-02-23       Impact factor: 22.113

4.  Telomere shortening associated with increased genomic complexity in chronic lymphocytic leukemia.

Authors:  Patricia Dos Santos; Julieta Panero; Virginia Palau Nagore; Carmen Stanganelli; Raimundo F Bezares; Irma Slavutsky
Journal:  Tumour Biol       Date:  2015-05-26

5.  Absolute qPCR for measuring telomere length in bone marrow samples of plasma cell disorders.

Authors:  Julieta Panero; Nathan J O'Callaghan; Michael Fenech; Irma Slavutsky
Journal:  Mol Biotechnol       Date:  2015-02       Impact factor: 2.695

Review 6.  Leukocyte Telomere Length and Pancreatic Cancer Risk: Updated Epidemiologic Review.

Authors:  Samuel O Antwi; Gloria M Petersen
Journal:  Pancreas       Date:  2018-03       Impact factor: 3.327

7.  Telomere length in prospective and retrospective cancer case-control studies.

Authors:  Karen A Pooley; Manjinder S Sandhu; Jonathan Tyrer; Mitul Shah; Kristy E Driver; Robert N Luben; Sheila A Bingham; Bruce A J Ponder; Paul D P Pharoah; Kay-Tee Khaw; Douglas F Easton; Alison M Dunning
Journal:  Cancer Res       Date:  2010-04-15       Impact factor: 12.701

8.  Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms.

Authors:  Sarah K Brennan; Qiuju Wang; Robert Tressler; Calvin Harley; Ning Go; Ekaterina Bassett; Carol Ann Huff; Richard J Jones; William Matsui
Journal:  PLoS One       Date:  2010-09-01       Impact factor: 3.240

Review 9.  Association between telomere length and survival in cancer patients: a meta-analysis and review of literature.

Authors:  Xinsen Xu; Kai Qu; Qing Pang; Zhixin Wang; Yanyan Zhou; Chang Liu
Journal:  Front Med       Date:  2016-05-16       Impact factor: 4.592

Review 10.  Multiple myeloma cancer stem cells.

Authors:  Carol Ann Huff; William Matsui
Journal:  J Clin Oncol       Date:  2008-06-10       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.